RxDoctor Payments Data

Tushar Patel, MD

Ophthalmology · Mooresville, NCNPI 1922012103

Payments from drug & device makers

$7,481in general payments, 2019–2025

Across 194 payments — averaging $38.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$4K
  • Amgen$834
  • Aerie Pharmaceuticals, Inc.$632
  • AbbVie$612
  • Bausch & Lomb Americas Inc.$345
  • Kala Pharmaceuticals, Inc.$227
  • plus $1K from 12 others

What the payments were for

  • Food & beverage$7,42399%
  • Education$240%
  • Entertainment$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,481 in reported general payments places this provider in the 80th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$702,252
Medicare patients
1,743
Services billed
6,607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine68$76,114
RocklatanNetarsudil Mesylat/Latanoprost117$60,210
LumiganBimatoprost62$38,104
XiidraLifitegrast25$33,077
CombiganBrimonidine Tartrate/Timolol57$27,230
Prednisolone Acetate907$25,405
Latanoprost1,339$18,515
Cyclosporine18$14,305
Travoprost71$14,232
RhopressaNetarsudil Mesylate39$12,407
Timolol Maleate852$11,185
Tobramycin-DexamethasoneTobramycin/Dexamethasone232$10,955
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$9,946
VyzultaLatanoprostene Bunod12$9,039
Diclofenac Sodium834$8,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$612$147,263202 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$632$72,617156 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$345$42,11637 claims
AlconSimbrinza$3,814$8,09733 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$93$6,78934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →